Silverback Therapeutics and ARS Pharma to merge

22 July 2022
silverbacktx_large

USA-based biopharma firm Silverback Therapeutics (Nasdaq: SBTX) and ARS Pharmaceuticals have entered into a definitive agreement under which ARS will merge with Silverback in an all-stock transaction.

Shares of Silverback traded down more than 10% to $3.94 in after-hours activity yesterday. Earlier this year the company also fell back, when it announced that it is shutting down its targeted oncology programs and cutting its workforce by 27% as it refocuses resources on developing chronic hepatitis B drugs and its ImmunoTAC drug discovery platform. It also reported a net loss of $89.5 million for 2021 compared to a net loss of $32.9 million in 2020.

The combined company will focus on the potential regulatory approval and commercialization of neffy, ARS’s investigational epinephrine nasal spray for the treatment of Type I allergic reactions including anaphylaxis.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology